Free Trial
ETR:MDG1

Medigene (MDG1) Stock Price, News & Analysis

Medigene logo
€0.13 0.00 (0.00%)
As of 04/30/2025

About Medigene Stock (ETR:MDG1)

Key Stats

Today's Range
€0.13
€0.13
50-Day Range
€0.13
€1.75
52-Week Range
€1.60
€5.51
Volume
N/A
Average Volume
306,207 shs
Market Capitalization
$1.02 million
P/E Ratio
N/A
Dividend Yield
1.31%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

MDG1 Stock Analysis - Frequently Asked Questions

Medigene's stock was trading at €1.03 at the beginning of the year. Since then, MDG1 stock has decreased by 87.0% and is now trading at €0.13.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ETR:MDG1
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
7.12
Net Income
$-4,667,238.14
Net Margins
-249.83%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.87 million
Cash Flow
€0.10 per share
Price / Cash Flow
1.37
Book Value
€0.72 per share
Price / Book
0.18

Miscellaneous

Free Float
N/A
Market Cap
$1.02 million
Optionable
Not Optionable
Beta
0.84
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (ETR:MDG1) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners